Inflammatory bowel disease (IBD) is characterized by a chronic inflammation of the gut, partly driven by defects in the expression and function of pattern recognition receptors, including the IFI16 protein. Because this protein is a target for autoantibodies and its aberrant expression was reported in colonic mucosa from active patients with ulcerative colitis, we studied its expression and specific seroresponse in patients with IBD before and after infliximab (IFX) therapy.
Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy
CANEPARO, Valeria;LANDOLFO, Santo Giuseppe;DE ANDREA, Marco
Last
2016-01-01
Abstract
Inflammatory bowel disease (IBD) is characterized by a chronic inflammation of the gut, partly driven by defects in the expression and function of pattern recognition receptors, including the IFI16 protein. Because this protein is a target for autoantibodies and its aberrant expression was reported in colonic mucosa from active patients with ulcerative colitis, we studied its expression and specific seroresponse in patients with IBD before and after infliximab (IFX) therapy.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Caneparo et al_manuscript.docx
Accesso riservato
Descrizione: Articolo principale
Tipo di file:
PREPRINT (PRIMA BOZZA)
Dimensione
72.41 kB
Formato
Adobe PDF
|
72.41 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
Caneparo et al_manuscript.pdf
Accesso aperto
Descrizione: Articolo principale
Tipo di file:
PREPRINT (PRIMA BOZZA)
Dimensione
357.34 kB
Formato
Adobe PDF
|
357.34 kB | Adobe PDF | Visualizza/Apri |
|
DeA Bowel pdf editoriale.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
939.5 kB
Formato
Adobe PDF
|
939.5 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
